Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib Plus Hydroxychloroquine in KRAS Mutant Metastatic Pancreatic Cancer
NCT04132505Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2019
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib and hydroxychloroquine in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Oct 2019; status: completed.
02
Drugs
binimetinibhydroxychloroquine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04132505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132505.